Biotech's Outlook Brightens, But Lab Landlords Face Deepening Vacancies, Falling Rents

Why It Matters

The split between biotech financing strength and lab‑space oversupply signals risk for investors and landlords, while conversion trends may reshape the life‑science real‑estate landscape.

Key Takeaways

• Nationwide lab vacancy rose to 23.2% in Q1 2026.
• Asking rents fell to $67 per square foot, fifth quarter drop.
• 55.6% of labs built 2020‑2025 remain empty.
• VC funding hit $7.5 B in Q1, spurring biotech hiring.
• Landlords repurpose 1 M SF of space for tech and manufacturing.

Pulse Analysis

Biotech’s financing engine roared back to life in early 2026, with venture capital pouring $7.5 billion into the sector—well above the two‑year average—and a string of high‑profile IPOs that raised more than $1 billion collectively. Hiring momentum followed, as life‑science firms added staff at a 2% annual growth rate, the strongest pace since mid‑2023. This capital influx fuels research pipelines and positions biotech firms for longer‑term expansion, reinforcing the sector’s appeal to investors seeking growth beyond traditional tech hubs.

Contrasting the funding surge, the life‑science real‑estate market is grappling with a severe supply‑demand mismatch. CBRE data shows vacancy climbing to 23.2% nationwide, while asking rents slipped to $67 per square foot for the fifth straight quarter. More than half of the 60 million square feet of labs constructed between 2020 and 2025 sit idle, and the 2025‑vintage inventory is over 70% vacant. These figures underscore a lingering lag as companies await clearer signals from the broader economy before committing to new lab space, pressuring landlords to lower rates and offer more flexible terms.

In response, owners are repurposing idle labs for heavy‑tech, advanced manufacturing and AI‑focused office use, converting roughly 1 million square feet to alternative functions. This adaptive reuse helps offset the vacancy glut while attracting a broader tenant base. Analysts expect the bifurcated market to converge as biotech funding stabilizes and the economy improves, potentially narrowing the vacancy gap and restoring confidence in life‑science real estate. Stakeholders should monitor leasing velocity, conversion activity, and funding cycles to gauge when the sector may return to a more balanced growth trajectory.